Unifiram

Unifiram is a nootropic agent.¹ It increases acetylcholine (ACh) release in the rat cerebral cortex in vivo and induces a long-lasting increase in the amplitude of field excitatory postsynaptic potentials (fEPSPs) in the rat hippocampal CA1 region (EC₅₀ = 27 nM). It does not bind to serotonin (5-HT), dopamine, muscarinic, nicotinic, adrenergic, glutamate, histamine, opioid, or GABA receptors at 1 µM. Unifiram (0.1 mg/kg) improves memory in non-memory-impaired rats in a social learning test.² It also prevents memory deficits induced by the anticholinergic agent scopolamine, nicotinic receptor antagonist mecamylamine, GABA_B receptor agonist baclofen, or α₂-adrenergic receptor agonist clonidine in the passive avoidance test in mice when administered at a dose of 0.01 mg/kg and prevents memory deficits induced by the AMPA/kainate glutamate receptor antagonist NBQX at 0.1 mg/kg.¹

WARNING This product is not for human or veterinary use.

1. Romanelli, M.N., Galeotti, N., Ghelardini, C., et al. Pharmacological characterization of DM232 (unifiram) and DM235 (sunifiram), new potent cognition enhancers. CNS Drug Rev. 12(1), 39-52 (2006).

2. Ghelardini, C., Galeotti, N., Gualtieri, F., et al. The novel nootropic compound DM232 (unifiram) ameliorates memory impairment in mice and rats. Drug Develop. Res. 56(1), 23-32 (2002).